Soleno Therapeutics(SLNO)

• Commercial growth opportunity: $190M revenue in FY2025 with VYKAT XR in growth phase (LOE 2035) provides 10+ years of runway
• Focused pipeline with clear catalysts: Four Phase 3 trials underway in Prader-Willi Syndrome, a rare but addressable genetic obesity indication
• Public company stability with adequate cash: $88M cash position as of FY2025 allows execution without immediate dilution pressure

Generated by Claude from Soleno Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.